pressetextpressetext

PTA-PVR: Leo International Precision Health Aktiengesellschaft: Announcement for Announcements of holders of considerable holdings according to article 43 WpHG

Refinitiv閱讀1分鐘

Leo International Precision Health Aktiengesellschaft

by Phillip Campbell

Announcements of holders of considerable holdings according to article 43 WpHG Garching (pta/14.07.2025/19:00) - Release of Release according to § 43 WpHG Notification of Holdings Mr. Ding-Shin Chang, Levallois-Perret, France, notified us on July 2, 2025, in accordance with Section 43 (1) of the German Securities Trading Act (WpHG) of the following: 1. The investment serves to implement strategic objectives. 2. I intend to acquire further voting rights within the next twelve months through acquisition or by other means. 3. I seek to influence the composition of the issuer's executive and supervisory bodies. 4. I do not intend to make any significant changes to the capital structure, in particular with regard to the ratio of equity and debt financing or the dividend policy. 5. The acquisition of voting rights in Leo International Precision Health Aktiengesellschaft was effected by attributing the shareholding of SGCI Corporate Finance GmbH in accordance with Sec. 34 para. 1 sent. 1 no. 1 of the German Securities Trading Act (WpHG) and by attributing the shareholding of Mr Hsiao-Hsuan Wang in accordance with Sec. 34 para. 2 of the German Securities Trading Act (WpHG). I have not directly used third-party funds or own funds to acquire voting rights in Leo International Precision Health Aktiengesellschaft. (end) emitter: Leo International Precision Health Aktiengesellschaft address: Dieselstraße 21, 85748 Garching country: Germany contact person: Phillip Campbell e-mail: vorstand@spobag-ag.de ISIN(s): DE0005490601 (share) stock exchanges: regulated market in Dusseldorf, Frankfurt pressetext Nachrichtenagentur GmbH Ad-hoc and financial news distributed by pressetext.adhoc. Archive: http://adhoc.pressetext.com The emitter is responsible for the content. Contact: adhoc@pressetext.com or +43-1-81140-0.
登入或建立一個永久免費帳戶來閱讀此新聞